Sanofi SA's Fiscal Year is From January To December - All Figures are in EUR, Billions.
The item "End-Period-Cash-Flow" stands at 39.85 Billion Euros for the trailing twelve months (TTM) period ending 09/30/2025, the highest value since 12/31/2023.
Sanofi SA's third quarter result of 8.91 Billion EUR for the item "End Period Cash Flow" represents a decrease of -42.01 percent compared to it's second quarter result.
Also, Sanofi SA's third quarter result of 8.91 Billion EUR for the item "End Period Cash Flow" represents an increase of 31.07 percent compared to it's third quarter result of last year.
Looking again at the trailing twelve months series (TTM), Sanofi SA's third quarter result of 39.85 Billion EUR for the item "End Period Cash Flow" represents an increase of 5.59 percent compared to it's second quarter result.
Regarding the One-Year-Change of the series, the current value constitutes an increase of 28.51 percent compared to the value the year prior.
The 1 year change in percent is 28.51.
The 3 year change in percent is 17.23.
The 5 year change in percent is -21.94.
The 10 year change in percent is 335.64.
| Logo | Name | Market Cap (USD) |
|---|---|---|
![]() | Eli Lilly and Company - End Period Cash Flow | 905,699,262,464.00 |
![]() | Johnson & Johnson - End Period Cash Flow | 486,508,953,600.00 |
![]() | AbbVie Inc - End Period Cash Flow | 399,570,305,024.00 |
![]() | Roche Holding AG - End Period Cash Flow | 317,433,206,677.55 |
![]() | AstraZeneca PLC - End Period Cash Flow | 280,205,508,085.11 |